作者
Ashvini Keshavan, Henrietta Wellington, Zhongbo Chen, Ayesha Khatun, Miles Chapman, Melanie Hart, David M Cash, William Coath, Thomas D Parker, Sarah M Buchanan, Sarah E Keuss, Matthew J Harris, Heidi Murray‐Smith, Amanda Heslegrave, Nick C Fox, Henrik Zetterberg, Jonathan M Schott
发表日期
2021
期刊
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
卷号
13
期号
1
页码范围
e12131
简介
INTRODUCTION
We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with pre‐symptomatic Alzheimer's disease (AD) pathology on amyloid positron emission tomography (PET).
METHODS
In 72 individuals from the Insight 46 study, CSF Aβ40, Aβ42, total tau (t‐tau), and phosphorylated tau at site 181 (p‐tau181) were measured using Lumipulse, INNOTEST, and Meso Scale Discovery (MSD) assays and inter‐platform Pearson correlations derived. Lumipulse Aβ42 measures were adjusted to incorporate standardization to certified reference materials. Logistic regressions and receiver operating characteristics analysis generated CSF cut‐points optimizing concordance with 18F‐florbetapir amyloid PET status (n = 63).
RESULTS
Measurements of CSF Aβ, p‐tau181, and their ratios correlated well across platforms (r 0.84 to 0 …
学术搜索中的文章
A Keshavan, H Wellington, Z Chen, A Khatun… - Alzheimer's & Dementia: Diagnosis, Assessment & …, 2021